Edition:
United States

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

15.91USD
4:00pm EDT
Change (% chg)

$0.48 (+3.11%)
Prev Close
$15.43
Open
$15.59
Day's High
$16.18
Day's Low
$15.59
Volume
26,326
Avg. Vol
21,246
52-wk High
$20.31
52-wk Low
$6.20

Latest Key Developments (Source: Significant Developments)

Obseva SA Achieves Primary And Secondary Endpoints For Edelweiss Phase 2B Clinical Trial Of Linzagolix
Monday, 18 Jun 2018 07:00am EDT 

June 18 (Reuters) - Obseva SA ::OBSEVA SA ACHIEVES PRIMARY AND SECONDARY ENDPOINTS FOR EDELWEISS PHASE 2B CLINICAL TRIAL OF LINZAGOLIX (OBE2109) IN WOMEN WITH ENDOMETRIOSIS.OBSEVA SA - LINZAGOLIX WAS OBSERVED TO BE SAFE AND WELL TOLERATED IN PHASE 2B CLINICAL TRIAL.  Full Article

Obseva SA To Seek Six Share Listing
Friday, 1 Jun 2018 07:00am EDT 

June 1 (Reuters) - Obseva SA ::OBSEVA SA TO SEEK SIX SHARE LISTING.OBSEVA SA - INTENTION TO REQUEST LISTING OF SHARES ON SIX SWISS EXCHANGE UNDER SIX'S INTERNATIONAL REPORTING STANDARD.OBSEVA SA - TRADING OF OBSEVA'S SHARES ON NASDAQ WILL CONTINUE IN ADDITION TO SIX LISTING.  Full Article

Obseva Reports Q1 Loss Per Share $0.54
Wednesday, 16 May 2018 07:00am EDT 

May 16 (Reuters) - Obseva SA ::OBSEVA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.54.Q1 EARNINGS PER SHARE VIEW $-0.47 -- THOMSON REUTERS I/B/E/S.SAYS AS OF MARCH 31, 2018, OBSEVA HAD CASH AND CASH EQUIVALENTS OF $95.4 MILLION..  Full Article

Obseva Q4 Loss Per Share $0.48
Friday, 9 Mar 2018 07:00am EST 

March 9 (Reuters) - Obseva Sa ::OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.48.Q4 EARNINGS PER SHARE VIEW $-0.56 -- THOMSON REUTERS I/B/E/S.  Full Article

Obseva Initiates Phase 2A Clinical Trial Of Obe022 In Preterm Labor
Tuesday, 5 Dec 2017 07:00am EST 

Dec 5 (Reuters) - Obseva Sa ::OBSEVA INITIATES PROLONG, THE PHASE 2A CLINICAL TRIAL OF OBE022 IN PRETERM LABOR.OBSEVA SA - ‍OBSEVA EXPECTS TO ANNOUNCE PRELIMINARY RESULTS FROM 60 PATIENTS IN PART B OF PROLONG TRIAL IN LATE 2018​.  Full Article

ObsEva SA files for resale of up to 7.5 million common shares‍​
Thursday, 9 Nov 2017 06:27pm EST 

Nov 9 (Reuters) - Obseva Sa :ObsEva SA - files for resale of up to 7.5 million common shares‍​ of co by the selling shareholders - SEC filing.  Full Article

ObsEva SA announces $60 mln private placement with existing and new investors
Tuesday, 10 Oct 2017 08:01am EDT 

Oct 10 (Reuters) - ObsEva SA : :ObsEva SA announces $60.0 million private placement with existing and new investors.ObsEva SA - ‍common shares in offering are priced at $8.00 per share.ObsEva SA - ‍net proceeds from offering are expected to be used to fund research,development of lead compound OBE2109, among others​.  Full Article

ObsEva Q2 loss per share $0.61
Tuesday, 15 Aug 2017 04:05pm EDT 

Aug 15 (Reuters) - ObsEva SA :ObsEva reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.61.Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article

ObsEva SA announces pricing of initial public offering
Wednesday, 25 Jan 2017 11:07pm EST 

ObsEva SA : Announces pricing of initial public offering .Announced pricing of its initial public offering of 6.45 million common shares at initial public offering price of $15 per share.  Full Article

ObsEva plans Swiss listing; trading debut on July 13

ZURICH ObsEva , a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.